Boya Bio released its 2026 interim report, with net profit attributable to the parent company of 51.19 million yuan, a year-on-year decrease of 77.28%. The company's total operating revenue was 644 million yuan, down 36.14% year-on-year; net cash flow from operating activities was negative 136 million yuan, down 2,062.30% year-on-year. The company's latest asset-liability ratio was 10.15%, gross margin was 44.21%, ROE was 0.69%, and diluted earnings per share was 0.10 yuan.
China Resources Boya Bio pharmaceutical Group Co LtdNet profit down 77.28% YoY, revenue down 36.14%, operating cash flow deeply negative.